Abstract: Angiotensin II is well known to affect the adrenal cell growth and function. Angiotensin receptors AT1 and AT2 were found to be present in the normal adrenal gland. However, the data on the expression of the angiotensin receptors in the adrenal tumors are very scarce. To overcome this gap, the paraffin sections of the adrenal cortical tumors and of pheochromocytomas from the archival material were immunostained with antibodies raised against AT1 (sc-1173) and AT2 (sc-9040) receptor proteins. In hyperplasia of the adrenal cortex and in benign adrenocortical adenomas, both functioning and non-functioning, the AT1 immunostaining was present mainly in the cell membranes. A positive immunoreaction was also found in the subpopulation of cell nuclei and within the cytoplasm. In the adrenal cancer, as well as in pheochromocytomas, neither cell membranes nor cell nuclei were immunostained with anti-AT1 antibody. However, a weak AT1 immunostaining was present within the cytoplasm of tumoral cells. With anti-AT2 antibody, in all tumors investigated, the tumoral cells were immunonegative but moderate to strong AT2 immunostaining was observed in the walls of intratumoral blood vessels and in the interstitial tissue. Our data indicates that the expression of AT1 receptors is altered in adrenal cancer and in pheochromocytomas. The expression of AT2 receptors, in turn, may be connected with the process of tumoral neo-angiogenesis.
Introduction
The adrenal gland is well known to be a target for angiotensin II (Ang II). Ang II is the main regulator of aldosterone secretion and exerts the stimulatory effect on the adrenal cell growth [1] [2] [3] . Although the adrenal gland is affected by circulating Ang II, the peptide can be also generated within the gland by a local reninangiotensin system [4, 5] . Both main subtypes of Ang II receptors, AT1 and AT2 were identified in rodent and human adrenal cortex and medulla [6] [7] [8] . In adrenal cortex, AT1 subtype is prevalent, whereas in adrenal medulla the AT2 subtype dominates [6] . Despite the important roles of Ang II and its receptors in the adrenal physiology, the data on angiotensin receptors in the adrenal tumors are rather scarce and partly controversial [9] [10] [11] [12] [13] [14] .These investigations were performed by means of radioligand binding or by means of molecular biology techniques, mainly polymerase chain reaction (PCR). On the other hand, the study performed by means of immunohistochemistry is lacking. The present paper reports, for the first time, the expression of angiotensin receptors AT1 and AT2 in human adrenal tumors as revealed by immunohistochemistry.
Materials and methods
Tumor material. The archival material of 26 surgically excised adrenal tumors in years 2001-2006, stored in paraffin blocks was studied. The material included 3 hyperplasias, 8 non-functioning cortical adenomas, 3 cortical adenomas manifesting themselves as primary hyperaldosteronism (Conn's syndrome), 4 cortisol-secreting adrenocorical adenomas, causing the Cushing's syndrome, 3 hormonally non-functioning adrenal cancers and 5 pheochromocytomas. In addition, 6 non-tumoral adrenal glands were studied. Five of them were removed from patients suffering from renal cancers during the surgical excision of the affected kidney, and one was excised together with pheochromocytoma.
Immunohistochemistry. The paraffin sections were immunostained with antibodies raised against AT1 and AT2 receptor proteins. AT1 immunostaining was performed using the anti-AT1 polyclonal antibody (sc-1173), raised against the N-terminal extracellular domain of AT1 receptor and recognizes human, rat and mouse receptor protein. AT2 receptors were revealed using the sc-9040 polyclonal antibody raised against the 221-303 fragment of the human AT2 receptor protein. The antibody detects human, rat and mouse AT2 receptors. Both antibodies were pur-chased from Santa Cruz Biotechnology, CA, USA. The anti-AT1 and anti-AT2 antibodies were applied in working dilution 1:100. The visualization of primary antibodies was done using the StreptABComplex/HRP Duet (Dako Cytomation) following the procedure recommended by the producer. In brief, the biotinylated goat antibody against rabbit and mouse immunoglobulin was applied as the secondary antibody, followed by streptavidinbiotinylated horseradish peroxidase complex and 3,3'-diaminobenzidine as chromogen. The slides stained without the primary antibody served as controls. 
Results

The non-tumoral adrenal gland
The investigated fragments were limited to the adrenal cortex. The positive immunostaining with anti-AT1 antibody was found mainly in cell membranes. In the cytoplasm, a moderate staining was detectable in zona reticularis cells. In 3 from 6 examined glands, the subpopulation of the glandular cell nuclei (1%-31%) also immunostained with anti-AT1 antibody (Fig. 1) . With anti-AT2 antibody, in all specimens the cell membranes and cell nuclei were negative. A weak or moderate reaction was observed within the cytoplasm of zona reticularis cells in 3 from 6 glands (Fig. 2) . A weak reaction was also observable in capsule and interstitial connective tissue, and, in one case, also in the intra-glandular blood vessels.
Adrenocortical hyperplasia
In all the samples diagnosed as adrenocortical hyperplasia the reaction with anti-AT1 antibody was moderate to strong in cell membranes and weak to strong in cytoplasm. In all the cases a percentage of AT-1 positive cell nuclei was >15% (15%, 30% and 50%, respectively). On the other hand, there were no reactions with AT-2 antibody either in cell nuclei or in cytoplasm. The cell membranes were also immunonegative. In one case a weak reaction was also noticed in the interatial tissue and blood vessels.
Non-functioning cortical adenomas
The localization of AT1 receptors was roughly similar to that in normal adrenal cortex and adrenocortical hyperplasia. The cell membrane-located immunostain- ing was weak or strong, cytoplasmic immunostaining was weak except one case where the reaction was strong. The AT1-positive subpopulation of glandular cell nuclei was present in all but one tumor; its percentage varied from 2% to 50% of the nuclei. In all but one adenoma the reaction with anti-AT2 antibody was negative in cell membranes, cytoplasm and cell nuclei. In the remaining one case a strong AT2 immunopositivity in cell membranes was observed. In 4 from 8 adenomas , the variable AT2 immunopositivity was also found in blood vessels and the interstitial compartment.
Aldosterone-and cortisol-secreting adenomas
The adenomas removed from patients with Conn's syndrome presented moderate (in one case) or strong (2 cases) immunostaining of cell membranes with anti-AT1 antibody (Fig. 3) . The subpopulation of AT1-positive cell nuclei included 4%, 5% and 50%, respectively. The variable immunostaining was noticed within the glandular cell cytoplasm (weak, moderate or strong). In contrast, the glandular cells were negative with anti-AT2 antibody.
In the tumors from patients with Cushing's syndrome the variable cell membrane immunostaining was found: strong in 2 cases, weak in another 2 cases and negative in one case. A subpopulation of cell nuclei was AT1-positive in 3 cases (5%, 6% and 15% of nuclei, respectively). In the remaining two cases , sporadic (<1%) cell nuclei were also immunostained with AT1 antibody. With AT2 antibody, both aldosterone-and cortisol-secreting adenomas were immunonegative except for blood vessel and interstitial tissues in some cases (Fig. 4) .
Adrenal cancers
In adrenals cancers, neither cell membranes nor cell nuclei were immunostained with anti-AT1 antibody. However, the weak to moderate AT1 immunostaining was present within cytoplasm of the tumoral cells (Fig.  5) . With anti-AT2 antibody the tumoral cells were immunonegative, but in one case moderate to strong AT2 immunostaining was observed in the walls of intratumoral blood vessels and in the interstitial tissue (Fig. 6) .
Pheochromocytomas
In pheochromocytomas, neither cell membranes nor cell nuclei were immunostained with anti-AT1 antibody. The weak to moderate AT1 immunostaining was present within cytoplasm of the tumoral cells (Fig. 7) . With anti-AT2 antibody the tumoral cells in majority of cases were immunonegative. In one case the small population of cell nuclei (approx. 3%) was AT2-positive. In one case, a weak AT2 immunopositivity was also noticed within the cytoplasm. In majority of cases, a variable immunopositivity was also observed in the interstitial tissue and/or blood vessels walls (Fig. 8) .
Discussion
The data presented above confirm the earlier findings that AT1 receptors are present and prevalent over AT2 receptors in the normal human adrenal cortex. AT1 receptors are also expressed in benign adrenal tumors both non-functioning and hormone-secreting. This observation is compatible with some data from earlier papers. Tanabe et al. [8] and Kitamura et al. [12] reported on the expression of AT1 mRNAs in both aldosterone-and cortisol-secreting adenomas. Opocher et al. [11] studied the binding of labeled Ang II in presence or absence of specific receptor blockers concluded that Ang II receptors are present in both aldosterone-sereting and cortisol-secreting adenomas, but in the latter the receptor density is lower than in the normal adrenal tissue. In turn, Schubert et al. [14] showed the elevated expression of AT1 mRNA in functioning adrenal adenomas, higher than in the normal adrenal cortex, but a very low signal in non-functioning tumors. The latter observation stays in opposition to our finding that the functioning and non-functioning adrenal adenomas do not differ markedly in the AT1 immunostaining. In adrenal cancers, our main finding was the altered localization of AT1 immunoreactivity: disappearance of the membrane-linked and nuclear AT1 staining and slightly increased AT1 immunostaining within the cytoplasm. Such alterations, obviously, cannot be detected by means of PCR technique, which reflects only the global content of receptor mRNA. Moreover, the earlier findings concerning the adrenal cancers, obtained with PCR technique, were discordant: very low or undetectable signal in one study [11] and no significant changes according to the other [14] .
The nuclear AT1 immunostaining, observed sometimes in the normal adrenal cortex and in benign, but not in malignant adrenal lesions, is surprising. However, it is concordant with earlier observations indicating the presence of a nuclear binding site for Ang II and its AT1-like properties [15] . Although the role of this site is still unclear, its involvement in growth-promoting Ang II effects has been suggested [16] .
In pheochromocytomas AT1 immunostaining was detectable in tumoral cells but confined only to cytoplasm. In the earlier studies AT1 mRNA expression in pheochromocytoma was very low or undetectable [11] . In contrast to AT1 receptor protein, the AT2 immunostaining of tumoral cells is undetectable in almost all adrenocortical tumors and pheochromocytomas. The loss of AT2 immunoreactivity in pheochro-mocytomas may be of particular interest, since this subtype of angiotensin receptor is prevalent in the normal adrenal medulla.
Moreover, AT2 receptors were suggested to mediate the Ang II -induced inhibition of cell growth [17] . The strong reaction with AT2 antibody was found in some cases in the blood vessel walls and in the interstitial tissue. The reaction was absent in the control slides stained without primary antibody. However, the specificity of immunostaining in the interstitial tissue needs further investigations. If the discussed immunopositivity is specific, the earlier reports showing the expression of AT2 receptor mRNA in pheochromocytomas may be, at least in part, false positive. In turn, the strong expression of AT2 receptors in the walls of intratumoral vessels, as observed in some cases, was also reported by one of us in pituitary adenomas [18] . Interestingly, the AT2 block has been recently shown to inhibit retinal angiogenesis via suppression of the crucial factor involved in this processvascular endothelial growth factor (VEGF) [19] . It suggests that the vascular over-expression of AT2 may have a role in tumoral neo-angiogenesis in both pituitary and adrenal tumors.
To conclude, AT1 and AT2 receptors are expressed in benign adrenocortical tumors roughly similarly to the non-tumoral adrenal cortex. It means that Ang II may affect their function and growth and be involved in adrenal tumorigenesis. In contrast, in malignant adrenocortical tumors and in pheochromocytomas (which are often potentially malignant neoplasms) the expression of Ang II receptors is altered. This alteration may reflect the process of dedifferentiation linked with malignancy but may also have some pathophysiological consequences.
